Multiple molecular interactions redundantly contribute to RB-mediated cell cycle control by unknown
Thwaites et al. Cell Div  (2017) 12:3 
DOI 10.1186/s13008-017-0029-6
RESEARCH
Multiple molecular interactions 
redundantly contribute to RB-mediated cell 
cycle control
Michael J. Thwaites1,3, Matthew J. Cecchini1,3, Srikanth Talluri1,3, Daniel T. Passos1,3, Jasmyne Carnevale1,3 
and Frederick A. Dick1,2,3* 
Abstract 
Background: The G1-S phase transition is critical to maintaining proliferative control and preventing carcinogenesis. 
The retinoblastoma tumor suppressor is a key regulator of this step in the cell cycle.
Results: Here we use a structure–function approach to evaluate the contributions of multiple protein interaction 
surfaces on pRB towards cell cycle regulation. SAOS2 cell cycle arrest assays showed that disruption of three separate 
binding surfaces were necessary to inhibit pRB-mediated cell cycle control. Surprisingly, mutation of some interac-
tion surfaces had no effect on their own. Rather, they only contributed to cell cycle arrest in the absence of other pRB 
dependent arrest functions. Specifically, our data shows that pRB–E2F interactions are competitive with pRB–CDH1 
interactions, implying that interchangeable growth arrest functions underlie pRB’s ability to block proliferation. Addi-
tionally, disruption of similar cell cycle control mechanisms in genetically modified mutant mice results in ectopic 
DNA synthesis in the liver.
Conclusions: Our work demonstrates that pRB utilizes a network of mechanisms to prevent cell cycle entry. This has 
important implications for the use of new CDK4/6 inhibitors that aim to activate this proliferative control network.
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Background
Uninhibited cellular division is a feature of cancer cells. 
As such, pathways that regulate proliferation are typi-
cally disrupted in human cancer [1]. At a molecular 
level, the cell division cycle is frequently controlled by 
decisions made in the G1 phase [2]. Once through this 
phase, the cell is committed to DNA replication and ulti-
mately completion of cell division. The retinoblastoma 
gene product (pRB) has been shown to be a key regula-
tor of the restriction point that is responsible for control-
ling S-phase entry [3]. The best known function of pRB 
is the repression of E2F transcription factor activity [4]. 
RB performs this function by directly binding the trans-
activation domain of E2Fs, preventing the recruitment of 
transcriptional activators to influence gene transcription 
[4]. In addition, pRB can recruit chromatin regulating 
enzymes, such as histone deacetylases, to assist in tran-
scriptional repression [5]. This blocks gene expression 
that is necessary for DNA synthesis and cell cycle entry 
[2]. In the presence of mitogens cyclin dependent kinases 
phosphorylate pRB, changing its conformation and 
releasing E2Fs [6]. Free E2Fs are then able to stimulate 
transcription and S-phase progression. While this model 
describes cell cycle entry quite accurately, the role for the 
same molecular interactions between pRB and E2Fs in 
cell cycle exit is less clear as pRB dependent arrest can 
occur much faster than E2F repression [7].
The minimal interaction domain that mediates stable 
E2F binding to pRB is the large pocket, and this frag-
ment is also the minimal growth suppressing domain [8, 
9]. The large pocket is composed of three regions called 
A, B, and C [3]. The A and B domains of pRB form the 
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pocket in which the transactivation domain of E2Fs 
bind [10, 11]. In addition, pRB interacts with a number 
of chromatin regulators, including HDAC containing 
complexes, through a well conserved interaction site on 
the B box of pRB known as the LxCxE binding cleft [5]. 
This binding site is well defined for its ability to contact 
the LxCxE motif in viral oncoproteins [12]. Simultane-
ous interactions between E2Fs, pRB, and chromatin 
regulators through LxCxE interactions form the basis 
of active transcriptional repression through E2Fs. The 
C-terminus of pRB is largely unstructured and serves as 
a contact point for numerous protein interactions [3, 13]. 
It is required for stable interaction with E2F-DP dimers 
[14], as well as a unique interaction with the marked box 
domain of E2F1 [15]. Analysis of the large pocket of pRB 
has contributed to our knowledge of E2Fs in cell cycle 
control. However, there is little to reconcile how multi-
ple competing protein interactions through this domain 
contribute to pRB’s overall influence on cell proliferation.
Genetic ablation of RB causes defects in cell prolifera-
tion control in tissues and in primary cell culture experi-
ments [16, 17]. However, early studies of pRB-mediated 
cell cycle regulation exploited the RB null SAOS2 osteo-
sarcoma cell line [8, 9, 18]. RB expression in these cells 
leads to a robust accumulation of 2 N DNA content, indi-
cating a G1 arrest [19]. These studies looked at a variety 
of mutant versions of pRB in which strong cancer derived 
mutations were functionless, but low penetrance RB 
mutations retained the ability to at least partially restrict 
cell cycle entry [8, 9, 20, 21]. Surprisingly, the low pen-
etrance mutation R661W was defective for E2F binding, 
but retained the ability to inhibit cell cycle entry [20–22]. 
More recently, a number of studies have shown that the 
R661W mutant can regulate cyclin dependent kinase 
activity through p27, independent of E2F transcriptional 
control [7, 23]. Importantly, these studies established that 
the LxCxE binding cleft and C domains within the large 
pocket also mediate interactions with the anaphase pro-
moting complex and Skp2 to stabilize p27 expression [7, 
24]. Surprisingly, a unified model of how E2F dependent 
and independent proliferative control mechanisms inter-
act has yet to emerge.
To understand the importance of different protein 
interaction points in the RB large pocket, targeted muta-
tions to disrupt the LxCxE binding cleft [25–28], the 
canonical E2F binding site [29, 30], and pRB’s unique 
interaction with E2F1 in the C-terminus [31, 32], have 
been generated in mice. Analysis of proliferation in cells 
and tissues from these mutant animals suggests that indi-
vidual protein interactions play context specific roles. For 
example, LxCxE binding cleft mutant mice (called Rb1L, 
or Rb1NF) are viable with hyper proliferation largely lim-
ited to mammary ductal epithelium, that is likely due 
to unresponsiveness to growth inhibitory signals from 
TGF-β [33]. Importantly, these mice are not sponta-
neously cancer prone [27, 34], and they are capable of 
blocking E2F transcription under a number of physi-
ological circumstances [35]. However, repression of E2F 
targets is diminished following DNA damage, and the 
ability of these cells to enter senescence is compromised 
[35, 36]. Furthermore, mutagen treatment induces can-
cer in these mice under conditions where E2F repression 
fails [26]. Disruption of pRB’s unique E2F1 interaction in 
mice (called Rb1S) shows no detectable change in pro-
liferative control in tissues or isolated cells [32]. Lastly, 
mutational disruption of pRB–E2F interactions in Rb1G/G 
mice results in cells with accelerated entry into the cell 
cycle, but normal cell cycle exit [29, 30]. Remarkably, this 
mutation does not predispose mice to cancer [29], how-
ever, disruption of this interaction in combination with 
p27 deficiency deregulates cell cycle arrest functions 
and these mice are highly cancer prone [30]. This result 
is also provocative because the cell cycle arrest defects in 
Rb1G/G; p27 deficient compound mutants aren’t found in 
either single mutant strain alone. These data suggest that 
pRB dependent cell cycle arrest may depend on a com-
plex network of proliferative control signals such that loss 
of individual functions have limited effect on their own. 
This concept is underscored by the fact that no targeted 
knock in strain recapitulates the complete proliferative 
control and cancer susceptibility phenotypes of Rb1−/− 
mice. In this manuscript, we aimed to eliminate individ-
ual binding surfaces in the pRB large pocket to determine 
the extent that each contributes to cell cycle control 
alone and in combinations using SAOS2 arrest as a read 
out. Here, we demonstrate that multiple individual bind-
ing surfaces in the large pocket contribute to pRB-medi-
ated cell cycle control in cell culture, and provide proof 
of principle that this network functions endogenously to 
regulate DNA replication in the liver.
Methods
GST pulldowns and western blotting
C33A cells were transfected with either HA-E2F1-3 
(along with DP1), myc tagged CDH1 or pRB expression 
plasmids under the control of CMV promoters using 
standard calcium phosphate precipitation techniques. 
40 h after transfection cells were washed and collected in 
GSE buffer (20 mM Tris, pH 7.5, 420 mM NaCl, 1.5 mM 
MgCl2, 0.2 mM EDTA, 25% glycerol, 5 µg/mL leupeptin, 
5  µg/mL aprotinin, 0.1  mM Na3VO4, 0.5  mM NaF, and 
1  mM DTT) and frozen at −80  °C. Cell extracts were 
centrifuged and the supernatant was diluted twofold 
in low salt GSE (20  mM Tris, pH 7.5, 1.5  mM MgCl2, 
0.2 mM EDTA, 25 mM DTT, 0.1% NP-40) and combined 
with glutathione beads and recombinant fusion proteins. 
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GST-RB large pocket (amino acids 379–928) and GST-
HPV-E7 recombinant proteins were expressed and puri-
fied as previously described [29]. Beads were then washed 
twice with low salt GSE, boiled in SDS-sample buffer, 
resolved by SDS-PAGE, and western blotted. HA-tagged 
proteins were detected using anti-HA 3F10 (Roche), 
myc-tagged CDH1 was detected using monoclonal anti-
body 9E11, and pRB was detected with G3-245 (BD Phar-
magen). In order to test pRB stability, cells transfected 
with CMV expressed pRB were treated with 100 µg/mL 
cycloheximide for 24  h. Extracts were prepared in GSE 
buffer every 3 h up to 15 h. Extracts were spun down and 
western blotted for pRB.
SAOS2 cell cycle arrest assays
SAOS2 cells were transfected and harvested as previ-
ously described [37]. Briefly 106 cells were plated in 6 cm 
dishes and transfected with 0.15 µg of CMV-pRB, 1 µg of 
CMV-CD20 and 3.85 µg of CMV-β-gal, or 1 µg of CMV-
CD20 and 4 µg of CMV-β-gal as a negative control, using 
X-tremeGENE transfection reagent (Roche). Cells were 
re-plated onto 10 cm dishes 24 h after transfection, and 
harvested 48 h later. Cells were then stained with a fluo-
rescein conjugated anti-CD20 antibody to mark success-
fully transfected cells, as well as with propidium iodide 
(PI) to determine their DNA content. Flow cytometry 
was then performed to identify the percentage of CD20 
positive cells with 2 N DNA content as a measure of G1. 
In experiments expressing cell cycle arrest as percent 
change in G1, arrest data was scaled using CMV-pRB 
and CMV-β-gal as standards for maximal increase and 
unchanged G1 content allowing comparisons between 
different batches of experiments.
Animal housing, dissection and histology
All animals were housed and handled as approved by the 
Canadian Council on Animal Care. Mice were sacrificed 
at 8  weeks of age, dissected, and livers were processed 
for downstream applications. For histology, livers were 
fixed in formalin for 72 h followed by 72 h in PBS before 
being stored in 70% ethanol. Livers were then embedded 
in paraffin and five micron sections were cut and stained 
with Hematoxylin and Eosin. Images were captured on a 
Zeiss Axioskop 40 microscope and Spot Flex camera, and 
nuclear area in the livers was calculated using EyeImage 
software (Empix Imaging, Mississauga, Ontario, Canada).
Ploidy analysis of adult livers
A small piece of frozen liver was added to buffer A 
(25  mM Tris pH 7.5, 50  mM KCl, 2  mM MgCl2, 1  mM 
EDTA, 1  mM PMSF). Tissue was ground on ice with 
a mechanical tissue grinder. Tissue was then homog-
enized using a 1  mL dounce homogenizer and tight 
pestle. Nuclei were centrifuged at 12,000×g, then washed 
in buffer A and centrifuged. The pellet was then resus-
pended in Propidium Iodide solution (0.5  mg/mL PI, 
0.1% NP-40, 0.1% sodium citrate, 40 µg/mL RNase A in 
PBS). Samples were then analyzed by flow cytometry 
using standard methods to quantitate DNA content.
RNA isolation and E2F target gene quantification
RNA from livers was isolated using an RNeasy fibrous 
tissue kit (Invitrogen). Expression levels of the E2F target 
genes, Pcna, Ccne1 (cyclin E1), Ccna2 (cyclin A2), Tyms 
(thymidylate synthase), Mcm3, and Rbl1 (p107), were 
determined using the Quantigene Plex 2.0 reagent sys-
tem from Affymetrix (Santa Clara, CA) and a BioPlex200 
multiplex analysis system as previously reported [38]. 
Expression levels were normalized to the expression of 
β-actin.
BrdU staining of tissue sections
To analyze DNA replication, mice were injected with 
200  μL of 16  µg/mL BrdU (Sigma) in their peritoneal 
cavity 2  h before sacrifice. Livers were then isolated, 
fixed in formalin, embedded, and sectioned according 
as above. Sections were deparaffinized and rehydrated 
using a series of xylene and ethanol washes. The sec-
tions were brought to a boil in sodium citrate buffer and 
then maintained at 95  °C for 10  min. The cooled sec-
tions were rinsed in water three times for 5  min, and 
then rinsed in PBS for 5 min. The sections were blocked 
in phosphate buffered saline (PBS) supplemented with 
2.5% horse serum and 0.3% Triton X-100 for 1  h. The 
sections were then incubated with anti-BrdU antibodies 
(BD-Biosciences) in blocking buffer overnight at 4 °C and 
rinsed in PBS three times for 5 min each time. The slides 
were incubated with horse anti-mouse immunoglobulin 
G-fluorescein isothiocyanate (Vector) for 1 h and rinsed 
in PBS. The slides were then mounted with Vectashield 
plus DAPI (Vector). Fluorescent images were captured 
on a Zeiss Axioskop40 microscope and Spot Flex camera 
and colored using EyeImage software (Empix Imaging, 
Mississauga, Ontario, Canada), or a similar system.
Results
A cell culture assay demonstrates molecular redundancy 
of RB functions in proliferative control
Tumor suppression by the retinoblastoma protein has 
typically been associated with its ability to block cell 
cycle progression and repress E2F transcription factors 
[4]. However, defective E2F binding by pRB has been 
shown to have modest effects on proliferative control in 
SAOS2 cell culture experiments [15, 20–22], and gene 
targeted mouse models [29, 30]. In an attempt to describe 
the molecular interactions necessary for pRB-mediated 
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cell cycle arrest we investigated forms of pRB that were 
individually mutated at each of three distinct binding 
surfaces in the large pocket; the general E2F binding site 
(RBG), the E2F1 specific site (RBS), and the LxCxE bind-
ing cleft (using either the RBL or RBC mutations). Fig-
ure 1a diagrams pRB protein interactions and shows the 
relevant regions in each open reading frame that partici-
pate. Amino acid substitutions that are demonstrated to 
disrupt these contacts are shown in Fig.  1b [24, 37, 39, 
40], along with single letter nomenclature for each allele 
(e.g. RBG). Lastly, the types of interactions between pRB 
and E2Fs, or LxCxE motif proteins, are illustrated with 
the alleles that disrupt them individually shown on the 
right, and the intended effect of a combined mutant allele 
on the left (Fig. 1c).
GST-tagged versions of the pRB large pocket (GST-
RBLP, pRB amino acids 379–928) containing the 3 muta-
tions described above, as well as the triple mutant, were 
produced in bacteria. GST pulldowns were performed 
to test interaction defects predicted to occur in these 
mutants (Fig. 2a). RB deficient C33A lysates derived from 
transfections with the indicated E2Fs, or CDH1 were pro-
duced and used in pulldown experiments. As expected 
the RBG mutation disrupts binding of the activator E2Fs, 
E2F2 and E2F3. RBL disrupts the LxCxE binding cleft and 
is defective for binding the anaphase promoting complex 
targeting subunit CDH1. Finally, since E2F1 is capable of 
associating with pRB through two qualitatively different 
interactions, the general site and the specific site, bind-
ing is only lost following mutation of both sites in the 
triple mutant RBGSL. Full length pRB constructs contain-
ing these mutations were then transfected into SAOS2 
cells to determine their effectiveness in causing a G1 cell 
cycle accumulation. As previously shown, expression of 
wild-type pRB in SAOS2 cells lead to a build up of cells 
in G1 as determined by propidium iodide staining and 
flow cytometry (Fig.  2b) [19]. Expression of the mutant 
constructs of pRB had various levels of effectiveness for 
inducing a G1 cell cycle arrest (Fig. 2b). Notably, the RBS 
mutation showed a similar ability to block proliferation 
as wild-type RB (Fig. 2b). By contrast, disruption of the 
general binding pocket in the RBG mutant, or disruption 
of the LxCxE binding cleft (RBL) resulted in a significant, 
but partial decrease in the percentage of cells in the G1 
phase of the cell cycle (Fig.  2b). Importantly, no indi-
vidual mutation is able to completely disrupt RB func-
tion. However, when all three mutations were combined 
into one pRB molecule (RBGSL), the ability of pRBGSL to 
induce a G1 arrest was not statistically different from 
that of the β-Gal negative control (Fig.  2b). As disrup-
tion of the various interactions lead to an inability of 
pRB to bind to any of its LxCxE or E2F interactors, we 
next aimed to confirm that combination mutations led 
to disruption of these binding surfaces, as opposed to 
simply disrupting pRB structure or stability. To address 
this possibility, we used the RBC mutation that retains 
the ability to associate with HPV-E7, but has previously 
been shown to be defective for its interaction with CDH1 
[24]. Figure  2c demonstrates that both the RBC, and an 
RBGSC combination were able to maintain RB-E7 interac-
tion, suggesting this mutant combination retains it struc-
ture. Furthermore, the stability of the RBGSC mutation 
was determined by expressing both RBWT and RBGSC in 
Fig. 1 Interaction domains located in the large pocket of pRB and 
substitutions used in this study. a Linear diagrams of open reading 
frames for the indicated proteins highlighting the regions that medi-
ate interactions with pRB. pRB can bind E2F1-4 through the trans-
activation domain in the C-terminus of E2Fs known as the ‘general’ 
interaction. Alternatively, pRB can also bind the marked box domain 
of E2F1 through its C-terminal domain, termed the RB-E2F1 ‘specific’ 
interaction. b Locations of point mutations within the pRB open 
reading frame used in this study. RBG refers to mutations that disrupt 
the E2F general interaction, RBS is a mutation that disrupts the E2F1 
specific interaction. RBC and RBL both disrupt interactions through 
the LxCxE binding cleft. All codon numbers correspond to the 
human sequence. The large pocket domain is amino acids 379–928. 
c Diagram depicting the cell cycle control mechanisms that can be 
influenced by the 3 pRB binding surface mutations used in this study
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Fig. 2 Multiple point mutations are needed to overcome RB mediated cell cycle arrest. a GST-tagged RB large pocket proteins corresponding to 
the RBG, RBS, RBL, and RBGSL mutant versions of pRB were produced and purified. These GST-fusions were incubated with C33A extracts transfected 
with the indicated expression constructs. Bound proteins were isolated by precipitation and identified by western blotting. b Constructs contain-
ing full-length RB harboring the indicated mutations under the control of a CMV promoter were transfected into SAOS2 cells along with a CD20 
reporter. Cells were then stained with propidium iodide and the percentage of cells in G1 were determined by DNA content of CD20 positive cells. 
Bars indicate the mean of three separate experiments, and error bars indicate one standard deviation from the mean. Letters indicate groups that are 
significantly different from one another (ANOVA, Tukey test, p < 0.05). c Full length CMV-RB constructs were transfected into C33A cells and extracts 
were incubated with recombinant HPV-E7. Bound proteins were isolated by precipitation and western blotted to detect pRB. d Full length RBWT and 
RBGSC were transfected into C33A cells prior to cycloheximide treatment (CHX). Extracts were prepared over a 15 h time course and stability was 
monitored by Western blotting. e Constructs containing full-length RB harboring the various mutations, or combinations of mutations, under the 
control of a CMV promoter were transfected into SAOS2 cells along with a CD20 reporter. Cells were then stained with propidium iodide and the 
percentage of cells in G1 were determined by DNA content of CD20 positive cells. Bars indicate the mean of three separate experiments, and error 
bars indicate one standard deviation from the mean. f Transfections and cell cycle analysis were performed as in b and e, except the increase in G1 
cells is shown as Change in % G1 (relative to β-Gal control). Letters indicate groups that are significantly different from one another (ANOVA, Tukey 
test, p < 0.05)
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C33A cells. Cells were then treated with cycloheximide 
and protein was isolated over a period of 15 h. Western 
blots confirmed that RBWT and RBGSC have equal sta-
bility, further suggesting that these substitutions do not 
result in the misfolding and hence pleiotropic loss of pRB 
function (Fig. 2d). Finally, SAOS2 cell cycle arrest assays 
were performed using the RBC mutant alone or in dou-
ble and triple combinations (RBGC or RBGSC). As with the 
RBGSL mutant, the triple mutant combination RBGSC was 
unable to increase the proportion of G1 cells beyond that 
of β-Gal controls (Fig. 2e). In addition, SAOS2 cell cycle 
arrest following transfection with the RBGC and RBGS 
double mutants diminished the ability to induce a G1 
cell cycle arrest beyond any single mutant, but was less 
detrimental than the RBGSC combination (Fig. 2f ). These 
results demonstrate that pRB’s activity in this arrest 
assay can be defined through loss of individual protein 
interactions.
The combination of RBG and RBL mutations in RBGSL 
is more severe than either alone (Fig.  2b). It is difficult 
to envision LxCxE interaction defects enhancing loss of 
function of pRB-E2F binding defects through transcrip-
tional control since the RBG mutation already disrupts 
recruitment to E2F promoters [29, 30]. For this rea-
son, we investigated non-E2F dependent mechanisms 
that could be lost because of the RBL mutation such as 
binding to CDH1. In order to investigate how E2F and 
CDH1 dependent arrest mechanisms may relate to one 
another, we tested pRB’s ability to interact with each 
simultaneously. For this experiment we mixed C33A 
extracts containing myc-tagged CDH1 with increas-
ing amounts of HA-E2F3/DP1 extracts and tested their 
ability to bind to GST-RBLP in pulldown experiments 
(Fig.  3). This experiment reveals that increasing quanti-
ties of HA-E2F3/DP1 prevent myc-CDH1 from bind-
ing to GST-RBLP (Fig.  3, left side). Disruption of E2F3 
binding to pRB using a GST-RBLPG mutant prevents 
competition with myc-CDH1 for binding to pRB. This 
experiment suggests that pRB is unable to engage E2F3 
and CDH1 dependent functions simultaneously, suggest-
ing that these functions are interchangeable. This mirrors 
findings from recent in vivo approaches to pRB depend-
ent cell cycle control [30], and this will be explored fur-
ther in the discussion.
A compound mutant mouse model demonstrates 
molecular redundancy in RB control of DNA replication
Mutation of all three binding surfaces in the RB large 
pocket was required to maximally impair RB mediated 
cell cycle control (Fig. 2b, e). This finding, combined with 
the fact that individual mutations for each of these bind-
ing sites in gene targeted mice did not phenocopy the 
Rb1−/− proliferative control defects in primary cell cul-
ture, suggests that the function of pRB in cell cycle con-
trol may be composed of several distinct mechanisms 
[28, 29, 32]. To approximate the dysfunction of the RBGSL 
mutation in vivo as diagrammed in Fig. 1c, we combined 
our previously published Rb1G/G animals that disrupts 
Fig. 3 Competition between E2Fs and CDH1 for pRB binding. Purified GST-RBLP or an -RBLPG mutant was incubated with constant levels of 
myc-CDH1, and increasing quantities of HA-tagged E2F3/DP1 from transfected lysates. GST-pulldowns were performed and associated levels of 
myc-CDH1 and HA-E2F3/DP1 were determined by western blotting. Western blots using anti-pRB antibodies show the levels of GST-RBLP proteins 
precipitated in each experiment
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RB-E2F interactions with p27 null mice (Cdkn1b−/−) 
to eliminate its influence on cell cycle control [30]. In 
addition, we crossed these mice into an E2F1 null back-
ground to eliminate any effect on cell cycle regulation 
by the pRB-E2F1 specific interaction. This combination 
of mutations Rb1G/G; Cdkn1b−/−; E2f1−/−, represents 
one potential scenario of the effects of the RBGSL muta-
tion in  vivo on cell cycle control. Interestingly, Rb1G/G; 
Cdkn1b−/−; E2f1−/− (triple mutant) animals are viable 
and occur at normal Mendelian ratios (Table 1).
Since triple mutant mice did not phenocopy the embry-
onic lethality seen in Rb1−/− animals we next sought to 
determine if any tissues display loss of cell cycle control 
[41]. Previously, Mayhew et al. showed that tissue specific 
knockout of pRB in the murine liver resulted in the up 
regulation of E2F target genes and ectopic DNA replica-
tion, endoreduplication, and accumulation of nuclei with 
elevated ploidy [42]. Since hepatocytes often endoredu-
plicate it is possible to detect the accumulation of mis-
regulated DNA replication over time [35]. We therefore, 
aimed to analyze aspects of cell cycle control in the liv-
ers of Rb1G/G; Cdkn1b−/−; E2f1−/− animals to determine 
if these mutations were capable of disrupting pRB control 
of DNA replication. H&E staining of livers revealed that 
hepatocyte triple mutant adult livers had enlarged nuclei 
that on average were three times larger that wild-type 
and Rb1G/G; Cdkn1b−/− double mutant animals as well 
as twice as large as Rb1G/G and Rb1G/G; E2f1−/− nuclei 
(Fig.  4a, b). We also quantitated the density of hepato-
cytes per microscopic field of view and did not see sig-
nificant differences between genotypes (Fig.  3c). Since 
nuclear area in liver histology correlates with DNA con-
tent [43], this suggested elevated levels of endoreduplica-
tion in Rb1G/G; Cdkn1b−/−; E2f1−/− triple mutant livers. 
To test whether our triple mutant had elevated ploidy in 
their hepatocytes, nuclei were extracted from livers of 
Rb1+/+, Rb1G/G, and Rb1G/G; Cdkn1b−/−; E2f1−/− mice, 
stained with propidium iodine, and analyzed by flow 
cytometry for DNA content. Consistent with previous 
results we found that Rb1+/+ livers at 8 weeks of age dis-
play very low levels of 8 N DNA content, however triple 
mutant livers displayed a significant increase in the level 
of 8 N DNA at this time point (Fig. 4c), that is similar to 
what is reported when Rb1 is conditionally deleted in this 
organ [42]. This increase in nuclear size and subsequent 
DNA content indicates that triple mutant livers undergo 
endoreduplication. While this is a normal phenotype for 
liver cells over time, this suggests that the loss of these 
three regulatory elements controlled by pRB results in 
earlier endoreduplication, potentially due to a loss of cell 
cycle control.
We next wanted to determine the effect of our com-
bined mutations on the regulation of pRB functions 
related to cell cycle control. To accomplish this, RNA 
was isolated from adult livers to analyze the expression 
of E2F target gene transcription. Consistent with our 
previous findings, E2F target gene expression in Rb1G/G 
animals is higher than wild-type levels [29]. Interest-
ingly, triple mutant livers show high expression of some 
of these target genes (Fig.  4e). However, in some cases, 
E2F target gene expression is unchanged from wild type 
and this will be discussed later. To directly measure pro-
liferation in livers, 8-week-old animals were injected with 
BrdU to label nuclei with actively replicating DNA. Livers 
were dissected, sectioned and stained for BrdU incorpo-
ration. This analysis showed that while both Rb1G/G and 
Rb1G/G; Cdkn1b−/−; E2f1−/− livers display increases in 
the expression of E2F target genes only triple mutant liv-
ers displayed increased BrdU incorporation (Fig.  4e, f ). 
Taken together with the increased nuclear area and 8 N 
DNA content in triple mutant livers, these results sug-
gest that by mutating the general binding site of pRB, and 
eliminating both p27 and E2F1, we have recapitulated 
the DNA replication defects associated with conditional 
deletion of Rb1 in adult livers. These in vivo results also 
mirror the effects seen in the SAOS2 arrest assays that 
suggest that no individual protein interaction with pRB 
accounts for its activity in cell cycle control. Instead, 
these data indicate that pRB likely sits in the center of a 
network of regulators that control DNA replication and 
cell division.
Discussion
In this manuscript we aimed to further the under-
standing of pRB-mediated cell cycle control by disrupt-
ing pRB-binding interactions in the large pocket to 
quantitatively account for its arrest mechanisms. This 
Table 1 Frequency of compound mutant mice
The indicated genotypes of mice were crossed and all resulting progeny were 
genotyped. The number of live animals obtained at 2 weeks of age is indicated 
for each genotype and the expected number based on Mendelian inheritance is 
indicated in brackets
a  Indicates significance as determined by Chi squared test
E2f1−/−; Rb1G/+; Cdkn1b+/− × E2f1−/−; Rb1G/+; Cdkn1b+/−
Genotype P14
E2f1−/−; Rb1+/+; Cdkn1b+/+ 8 (13)
E2f1−/−; Rb1+/+; Cdkn1b+/− 29 (26)
E2f1−/−; Rb1+/+; Cdkn1b−/− 12 (13)
E2f1−/−; Rb1G/+; Cdkn1b+/+ 29 (26)
E2f1−/−; Rb1G/+; Cdkn1b+/− 64 (52)
E2f1−/−; Rb1G/+; Cdkn1b−/− 9a (26)
E2f1−/−; Rb1G/G; Cdkn1b+/+ 12 (13)
E2f1−/−; Rb1G/G; Cdkn1b+/− 35 (26)
E2f1−/−; Rb1G/G; Cdkn1b−/− 10 (13)
Total 208
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Fig. 4 Ectopic DNA-replication in Rb1G/G; Cdkn1b−/−; E2f1−/− compound mutant mice. a H&E staining of liver sections from 8-week old wild type, 
Rb1G/G, double mutant Rb1G/G; Cdkn1b−/−, and Rb1G/G; E2f1−/− mice, as well as Rb1G/G; Cdkn1b−/−; E2f1−/− triple mutant animals. The scale bars 
represent 20 μm. b Nuclear size from the images in a was determined and the mean size is indicated. Measurements were made from at least 50 
nuclei, a, b, c represents statistically different groups as determined by ANOVA followed by Tukey’s test (p < 0.05). c Total number of hepatocytes per 
20X field of view was averaged from the indicated genotypes. No statistical differences were observed by AVONA followed by Tukey’s test (p < 0.05) 
d Nuclei were extracted from livers, stained with propidium iodide, and analyzed for DNA content by flow cytometry. e The relative expression level 
of six E2F cell cycle target genes from wild type, Rb1G/G, and Rb1G/G; Cdkn1b−/−; E2f1−/− was determined from RNA extracted from 8-week-old livers. 
f 8-week-old mice were pulse labeled with BrdU 2 h prior to sacrifice and livers were sectioned and stained for BrdU. The percentage of BrdU posi-
tive nuclei was determined. At least 500 nuclei were counted per mouse. All bar graphs represent at least 3 individual experiments, and error bars 
indicate one standard deviation from the mean. An asterisk represents a statistically significant difference from the wild type control (t test, P < 0.05)
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structure–function analysis demonstrated that in order 
to disrupt the vast majority of pRB’s cell cycle arrest activ-
ity, three different binding surfaces needed to be altered. 
Surprisingly, no single interaction site was indispensible 
and disruption of some interaction sites had little effect 
on their own. We used a genetic cross to cripple these 
three aspects of pRB function endogenously and the 
combination caused ectopic DNA replication in the liver. 
This suggests that pRB may interchangeably use different 
protein interactions to influence cell cycle advancement. 
Insights and caveats of our study are discussed below.
It is difficult to predict the proliferative control defects 
of an Rb1 deficient mouse beyond neonatal lethality 
due to muscle atrophy [44]. Interestingly, chimeric mice 
composed of a mixture of wild type and Rb1−/− cells are 
viable and demonstrate normal tissue cellularity, even in 
organs where Rb1−/− cells contribute extensively [17]. 
This study reveals that livers containing Rb1−/− hepato-
cytes display random, large nuclei, similar to our findings 
in triple mutant livers [17]. In addition, conditional abla-
tion of Rb1 in the livers of adult mice is reported to cause 
unscheduled DNA replication [42]. The increase in DNA 
copy number and BrdU incorporation was indicative of 
a loss of regulation of DNA synthesis [42]. In an effort to 
model the effects of the RBGSL mutant in vivo, we com-
bined Rb1G/G animals with p27 and E2F1 deficiency to 
produce triple mutant animals (Rb1G/G; Cdkn1b−/−; 
E2f1−/−). This combination of mutations lead to a very 
similar DNA replication phenotype in the liver as com-
plete Rb1 deletion. While this is a similar phenotype as 
conditional deletion of Rb1, by no means does our study 
elucidate all that pRB pr E2Fs do to block the cell cycle 
in this or other tissues. We anticipate that viability of 
triple mutant mice suggests additional pRB dependent 
cell cycle arrest mechanisms likely remain functional in 
these animals. Another important consideration in our 
efforts to model the RBGSL mutant in vivo is that deleting 
Cdkn1b and E2f1 is not the equivalent to disrupting the 
binding sites on pRB that regulate them, as these interac-
tion sites may have additional regulatory effects beyond 
the downstream targets we have chosen. In addition, 
loss of E2F1 could diminish cell proliferation even when 
entry into S-phase is deregulated and this could further 
complicate the interpretation of our analysis of triple 
mutant livers. Importantly, others have demonstrated 
that the choice between proliferation and endoredupli-
cation in hepatocytes is determined by opposing effects 
of activator E2Fs (such as E2F1) and the E2F7 and E2F8 
repressors [45, 46]. It is difficult to predict how the triple 
mutant combination used here would affect the regula-
tion of this network of genes to cause a switch to endore-
duplication. Future experiments using Rb1 gene targeted 
mice carrying a combination of G, S, or L mutations in a 
single allele will help resolve some of these complexities.
We observed that some individual mutations contrib-
uted modestly to proliferative control alone, and more 
strongly when in combination with other substitutions. 
We suggest that this may be due in part to the competi-
tion between different cell cycle control mechanisms for 
access to pRB. For example, we demonstrate that E2F3 
and CDH1 can compete for the opportunity to interact 
with pRB, and this is consistent with previous reports of 
E2F1 and CDH1 competing for pRB [47]. We suggest that 
CDH1 interactions with pRB are fundamentally differ-
ent than other pRB interactors that contact the LXCXE 
binding site simultaneously with E2Fs [3]. Another way 
to consider redundancy of function through endogenous 
pRB is a gene targeted mouse model bearing an R654W 
mutation (the murine equivalent of the low penetrance 
human mutation R661W). This mutation not only dis-
rupts E2F binding, it also compromised interactions at 
the LXCXE cleft [20], potentially illustrating the effects 
of multiple mutations in a single pRB molecule akin to 
RBGC in our studies. Fibroblast cells from these mice pos-
sess many features of deregulated proliferation seen in 
Rb1−/− cells and this mutation is lethal during embryo-
genesis [48]. However, some aspects of pRB’s role in 
differentiation and its ability to respond to senescence 
inducing stimuli and resistance to tumor formation are 
retained [48, 49], suggesting that simultaneous deficiency 
by pRB for multiple interactions can reveal a more dra-
matic phenotype than loss of single interactions. This 
conclusion is further supported by deregulated cell cycle 
control and cancer incidence in Rb1G/G; Cdkn1b−/− mice 
[30], suggesting loss of multiple pRB dependent prolifera-
tive control pathways can be dramatically different than 
loss of a single pathway.
Consistent with multiple interactions needing to be 
compromised to abrogate cell cycle arrest by pRB, we 
also note that some mutations tested in this study, such 
as the M851A, V852A changes (RBS), have no effect on 
proliferative control in the SAOS2 assay on their own. 
We suggest that it may represent a latent proliferative 
control mechanism used by pRB, and there may be oth-
ers. A long standing puzzle in the RB field has been the 
existence of proliferative control mechanisms that are 
mediated by the N-terminus of pRB, outside of the orig-
inal growth suppressing large pocket domain [50–52]. 
Recent work has suggested that the N-terminus also 
plays a role in regulating DNA replication [52]. This may 
explain the phenotypic difference in proliferative con-
trol between Rb1−/− animals and that of triple mutant 
Rb1G/G; Cdkn1b−/−; E2f1−/− animals as the N-terminus 
is unaffected by our three mutations. There may also 
be redundancy between N-terminal and large pocket 
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growth arrest mechanisms. Provocatively, there are also 
low penetrance mutations in human RB1 that target 
this region of pRB; further suggesting the N-terminus 
contributes to pRB’s proliferative control and tumor 
suppressor functions [53]. We think that interchange-
ability of different pRB functions in proliferative control 
best explains our data and also encompasses additional 
work in the field that has previously been difficult to 
reconcile.
Conclusions
RB dependent proliferative control is functionally inacti-
vated in the vast majority of cancers, this study furthers 
our understanding of the importance of the various inter-
action surfaces of pRB and their roles in cell cycle con-
trol. In addition, CDK4/6 inhibitors have recently been 
developed to reactivate the RB-pathway in cancer [54–
56]. Understanding the molecular interactions made by 
pRB and how they influence cell cycle control and tumor 
suppression is crucial to the proper implementation of 
these drugs. We expect that the mutational status of both 
pRB, as well as its regulation of p27 and E2Fs, will play a 
critical role in the effectiveness of these drugs. We sug-
gest that patients whose tumor cells have pRB activatable 
p27 will benefit most from CDK4/6 inhibitors.
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